Antigenic changes of a murine lymphoma by in vivo treatment with triazene derivatives

✍ Scribed by M. C. Fioretti; B. Nardelli; R. Bianchi; C. Nisi; G. Sava

• Book ID: 104660338
• Publisher: Springer-Verlag
• Year: 1981
• Tongue: English
• Weight: 342 KB
• Volume: 11
• Category: Article
• ISSN: 0340-7004
• DOI: 10.1007/bf00198973

✦ Synopsis

Five aryltriazenes were studied for efficacy in mediating immunogenic changes of tumor cells by in vivo treatment of lymphoma-bearing mice. It was found that four analog compounds produced increase in cell immunogenicity similar to that described for 5- (3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC), one of the five being by contrast completely inactive. Moreover, the use of a drug-resistant lymphoma illustrates that cytotoxic activity is not mandatory for the appearance of the immunogenic changes.

The results show that a drug-mediated increase of tumor immunogenicity (DMITI) can be induced by triazene derivatives not containing the imidazole moiety.

of triazene compounds have been reported in the literature [3,8], but similar data on the generation of DMITI are lacking.

The present paper deals with studies on the efficacy of aryltriazenes in mediating the immunogenic changes of tumor cells by in vivo treatment of lymphoma-bearing mice.

The results show that the imidazole moiety present in DTIC is presumably not directly responsible for the generation of DMITI, since four analog triazene derivatives not containing the imidazole ring produced effects on cellular immunogenicity similar to those described for DTIC.